Browsing by Author Vercruysse, Frank

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2015Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled TrialFulcher, Greg; Neal, Bruce; Perkovic, Vlado; Capuano, George; de Zeeuw, Dick; Desai, Mehul; Mahaffey, Kenneth W; Matthews, David. R.; Meininger, G; Rosenstock, Julio; Shaw, Wayne; Vercruysse, Frank; Weiss, Robert; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthEfficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial, Diabetes Therapy, vol.6, 3, 2015,pp 289-302
2016Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetesFulcher, Greg; Neal, Bruce; Perkovic, Vlado; Capuano, George; de Zeeuw, Dick; Desai, Mehul; Mahaffey, Kenneth W; Mathieu, Chantal; Matthews, David. R.; Meininger, G; Shaw, Wayne; Vercruysse, Frank; Woo, Vincent; Wysham, C; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthEfficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes, Diabetes, Obesity and Metabolism, vol.18, 1, 2016,pp 82-91
2015Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 DiabetesFulcher, Greg; Neal, Bruce; Perkovic, Vlado; Alba, Maria; Capuano, George; de Zeeuw, Dick; Desai, Mehul; Jiang, Joel; Mahaffey, Kenneth W; Matthews, David; Meininger, G; Shaw, Wayne; Vercruysse, Frank; Ways, Kirk; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthEfficacy and Safety of Canagliflozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes, Diabetes Care, vol.38, 3, 2015,pp 403-411
2017Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trialFulcher, Greg; Neal, Bruce; Perkovic, Vlado; de Zeeuw, Dick; Deng, Hsiaowei; Desai, Mehul; Erondu, N; Mahaffey, Kenneth W; Matthews, David; Meininger, Gary; Shaw, Wayne; Vercruysse, Frank; Yee, Jacqueline; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthRationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial, Diabetes, Obesity and Metabolism, vol.19, 3, 2017,pp 387-393
2013Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trialFulcher, Greg; Neal, Bruce; Perkovic, Vlado; de Zeeuw, Dick; Desai, Mehul; Jiang, Joel; Mahaffey, Kenneth; Matthews, David; Meininger, G; Shaw, Wayne; Stein, Peter; Vercruysse, Frank; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthRationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial, American Heart Journal, vol.166, 2, 2013,pp 217-223